RNA製造とイノベーションの連携で、アジア太平洋地域での明確な道筋を構築

Whether you're an investor or a pharma leader, this is your chance to explore high-growth opportunities in Asia-Pacific markets, including oligos targeting CNS, circRNA, and RNA editing.

With countries like Japan, South Korea, and Singapore emerging as biotech innovation hubs, and China driving significant advancements in RNA therapeutics, the region offers unique opportunities for cross-border collaborations.

Connect with industry leaders in APAC and explore synergies with Western markets to uncover global trends and maximize your investment and partnering strategies in nucleic acids.

Explore groundbreaking FDA-approved mRNA therapies for gout and promising Phase 2 trials for inhaled mRNA targeting cystic fibrosis.

Dive into siRNA innovations tackling rare diseases like hereditary angioedema and muscular dystrophies. Uncover insights on regulatory hurdles, personalized n=1 trials, and China's remarkable progress in mRNA cancer vaccine ITT trials.

Dive into the transformative potential of mRNA therapeutics, including cancer vaccines, and oligonucleotides targeting rare diseases and broad-spectrum conditions like obesity.

Explore advancements in delivery beyond the liver, multi-platform approaches, and the role of AI in accelerating RNA drug discovery, such as addressing challenges in target selection.

Explore solutions to key RNA delivery challenges, such as stability, targeted tissue and cell delivery, and immune activation, with insights from APAC-based innovations. Learn from successes like the latest LNP-mRNA modifications and novel conjugates for oligonucleotides, improving tissue specificity.

Connect with drug delivery experts across Asia-Pacific, including leaders in Japan, South Korea, and Singapore, to unlock opportunities for advancing RNA therapeutics in the region.

Discover RNA’s role in precision medicine. Explore ASOs, siRNA, and miRNA for gene silencing and editing. Learn about RNA-binding proteins, small molecules, and CRISPR-based RNA editing.

Uncover how these innovations tackle challenges like specificity and delivery to address cancer, neurodegenerative disorders, and rare diseases.